Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been given an average rating of “Buy” by the six research firms that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $22.80.

A number of research analysts recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada dropped their price objective on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, March 26th. Finally, Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its position in Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock valued at $577,000 after acquiring an additional 33,013 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the period. MetLife Investment Management LLC raised its stake in shares of Lexeo Therapeutics by 121.5% during the third quarter. MetLife Investment Management LLC now owns 14,223 shares of the company’s stock worth $129,000 after purchasing an additional 7,803 shares during the last quarter. PDT Partners LLC acquired a new stake in shares of Lexeo Therapeutics during the third quarter worth $241,000. Finally, Janus Henderson Group PLC grew its position in Lexeo Therapeutics by 18.9% in the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Down 9.8 %

Shares of NASDAQ LXEO opened at $3.13 on Wednesday. The business has a 50-day moving average of $3.98 and a two-hundred day moving average of $6.44. The company has a market capitalization of $103.91 million, a price-to-earnings ratio of -0.99 and a beta of 3.85. Lexeo Therapeutics has a 1 year low of $2.32 and a 1 year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09. On average, analysts forecast that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.